top of page

Our Development Programs

Colorful Glass Objects

Lead program

Kanna Health is developing KH-001, a small molecule for the treatment of premature ejaculation.

 

Premature ejaculation (PE) is a distressing condition in which patients ejaculate too quickly before or shortly after penetration (often within less than a minute). There are currently no treatments approved by the FDA, despite the condition affecting up to 20% of men. These men report lower levels of sexual functioning and satisfaction, decreased self-esteem, and higher levels of personal distress. Partners of these men also suffer, and report sexual dissatisfaction and frustration, as well as problems in the relationship.          

KH-001 has shown promising results in proof-of-concept animal studies and entered the clinic in November 2023.

Discovery

Kanna Health is developing a proprietary library of new chemical entities (NCEs) whose pharmacological and pharmacokinetic properties can be fine-tuned to target a range of neuropsychiatric disorders with high unmet needs.

Abstract Background

Our pipeline

PROGRAM

DISCOVERY

PRE-CLINICAL

PHASE I

KH-001

KH-1XX series

bottom of page